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METRONOMIC CHEMOTERAPY 
Metronomic chemotherapy (MC) is an anti-tumor therapy. It is a conventional chemotherapy modification that uses lower 
anticancer drugs doses and minor breaks between them, so drugs are administrated daily or every few days. These changes allow 
to reduce toxicity, to avoid drug resistance and oral administration too. 
The project objectives are showing a new and booming  chemotherapy, their characteristics  and  to establish protocols for use 
thereof. 
 
 
INTRODUCTION & AIMS:  
ANTITUMOR EFFECTS 
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MOST COMMONLY USED DRUGS AND THEIR EFFECTS 
•↑ Tromboespondine 1 (TSP-1) 
•↓ Ciclooxigenase 2 (COX – 2) 
•↓Tirosin Kinase (TK) 
Inhibition of 
vasculogenesis and 
angiogenesis 
•↓ regulator T- Cells 
•↑ Dendritic cells 
•↑ Citotoxic T – Cells 
Activation of 
immunity 
Grade 1 
 Vomiting, Anorexia, Diarrhoea, Lethargy 
Grade 2 
Vomiting, Anorexia, Diarrhoea, 
↑ creatinine,  
Grade 3 
Neutropenia, Thrombocytopenia, Sterile 
hemorrhagic cystitis 
Grade 4 
Hemorrhagic colitis, sterile hemorrhagic 
cystitis (SHC) 
 
 
 
 
 
 
 
 
 
  Grade 5 
(the most severe) not shown 
Drug Antitumor Effects 
Ciclophosphamide ↑TSP-1, ↓recruitment CPEs, ↑Immune system 
Non Steroidal Anti Inflammatory Drugs ↓COX 
TK Inhibitors Block TK receptors 
 
 
Metronomic chemotherapy is not an attack therapy, it’s a maintenance treatment 
Experimental alternative to conventional chemotherapy against solid tumours, leukemia and metastatic 
tumours, with less toxicity. 
New attack 
targets are being 
looked for 
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Drug & Dosage + Adjuvant Tumour Outcome 
Ciclophosphamide (CYC)  12.5 – 25 mg/m²/24h 
3w + Etoposide + Piroxicam 
Hemangiosarcoma 
Median Survival Time (MST): 178 d. 
15% SHC 
CYC10 mg/m²/24 – 48h + Piroxicam 
 
Soft tissue sarcoma 
Minimum Disease- Free interval 
(MDFI): 410 d. [Without MC, only 
surgery MDFI: 211 d].  12% SHC 
CYC 12.5 - 15 mg/m²/24h +  None 
 
Soft tissue sarcoma Not assessed 
Chlorambucil  4mg/m²/24h + COX inhibitors or 
none 
transitional cell carcinoma of bladder 
Stable disease (SD): 67%, Partial 
response (RP): 3% MST: 221d. 
ADVERSE EFFECTS 
 
 
 
DRUGS,TUMOURS & OUTCOME IN DOGS 
